Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ:PASG)

7.300 -4.370 (-37.45%)
Streaming Delayed Price Updated: 1:30 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Passage Bio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces 1-for-20 Reverse Stock Split
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Welcomes Tom Kassberg to Board of Directors
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.